Yervoy 200mg 1s Injection

Vials per box: 1, Manufacturer: BMS


Composition Ipilimumab 200 mg
Substitutes Ipilimumab 200 mg
Shipping class Cold chain shipment

Medicine Overview of Yervoy 200mg 1s


Uses of Yervoy 200mg 1s

YERVOY is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.

Yervoy 200mg 1s side effects


Fatigue, diarrhea, pruritus, rash, colitis, headache, weight loss, nausea, pyrexia, decreased appetite, vomiting, insomnia; immune-mediated reactions; also with nivolumab: musculoskeletal pain, abdominal pain, cough, arthralgia, dyspnea.

How to use Yervoy 200mg 1s

It will be administered by a health care professional. Do not shake product. Inspect parenteral drug products visually for particulate matter and discoloration prior to administration. Discard vial if solution is cloudy, there is pronounced discoloration (solution may have pale-yellow color), or there is foreign particulate matter other than translucent-towhite, amorphous particles.

How Yervoy 200mg 1s works

CTLA-4 is a negative regulator of T-cell activity. Ipilimumab is a monoclonal antibody that binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation and proliferation of tumor infiltrating T-effector cells. Inhibition of CTLA-4 signaling can also reduce T-regulatory cell function, which may contribute to a general increase in T cell responsiveness, including the anti-tumor immune response.

In Depth Information on Yervoy 200mg 1s

Expert advice for Yervoy 200mg 1s

  • Severe and fatal immune-mediated adverse reactions can develop. Permanently discontinue therapy and initiate systemic high-dose corticosteroids for severe, persistent, or recurring immune-mediated reactions.
  • Withhold dose for moderate immune-mediated adverse reactions until return to baseline, improvement to mild severity, or complete resolution, and patient is receiving <7.5mg prednisone or equivalent per day. Monitor for enterocolitis, hepatitis, dermatitis, neuropathy, endocrinopathy, and others including ocular manifestations; perform clinical chemistries including LFTs, ACTH levels, and thyroid tests at baseline and before each dose.
  • Monitor for infusion reactions; discontinue if severe or life-threatening; interrupt or slow infusion rate if mild or moderate.
  • Give steroid eye drops if uveitis, iritis, or episcleritis develops (may need systemic treatment if a Vogt-Koyanagi-Harada-like syndrome develops); permanently discontinue if unresponsive to local therapy. Moderate or severe hepatic impairment.

Yervoy 200mg 1s related warnings

Special precautions for Yervoy 50mg 1s

There is no significant data. Please consult your doctor.
Pregnancy Category C
Females of reproductive potential should use effective contraception during and for 3 months after final dose.
For Nursing mother it is not recommended
YERVOY has minor influence on the ability to drive and use machines. Because of potential adverse reactions such as fatigue (see section 4.8), patients should be advised to use caution when driving or operating machinery until they are certain that ipilimumab does not adversely affect them.
There is no significant data. Please consult your doctor.
There is no significant data. Please consult your doctor.

What if you miss a dose of Yervoy 200mg 1s?

If you miss a dose of Yervoy, please contact your doctor.